EVOMELA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $51,222 | 4 | 0 |
| 2023 | $59,284 | 6 | 0 |
| 2022 | $100,866 | 4 | 0 |
| 2021 | $102,182 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $213,800 | 15 | 68.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $99,755 | 1 | 31.8% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Bayesian sequentially adaptive phase I/II trial to jointly optimize the administration schedule (s) and dose of Melphalan HCL for Injection (Propylene Glycol-Free melphalan) as a preparative regimen for autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma | Acrotech Biopharma LLC | $98,955 | 0 |
| IIS-MEL-005 | Acrotech Biopharma Inc. | $71,613 | 0 |
| IIS-MEL-004 | Acrotech Biopharma Inc. | $21,500 | 0 |
| IIS-MEL-003 | Acrotech Biopharma Inc. | $17,394 | 0 |
| A Phase II Single Center, Open-label, saferty and Effiacy study of Proplyene Glycol-Free Melphalan (Evomela) in AL Amylodiosis patients undegoing Autologous stem cell transplantation | Acrotech Biopharma LLC | $2,427 | 0 |
| A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan (Evomela) in AL amyloidosis Patients Undergoing Autologous Stem Cell Transplantation | Acrotech Biopharma LLC | $1,911 | 0 |
Top Doctors Receiving Payments for EVOMELA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $313,555 | 16 |
Manufacturing Companies
- Acrotech Biopharma LLC $203,048
- Acrotech Biopharma Inc. $110,506
Product Information
- Type Drug
- Total Payments $313,555
- Total Doctors 0
- Transactions 16
About EVOMELA
EVOMELA is a drug associated with $313,555 in payments to 0 healthcare providers, recorded across 16 transactions in the CMS Open Payments database. The primary manufacturer is Acrotech Biopharma LLC.
Payment data is available from 2021 to 2024. In 2024, $51,222 was paid across 4 transactions to 0 doctors.
The most common payment nature for EVOMELA is "Unspecified" ($213,800, 68.2% of total).
EVOMELA is associated with 6 research studies, including "A Bayesian sequentially adaptive phase I/II trial to jointly optimize the administration schedule (s) and dose of Melphalan HCL for Injection (Propylene Glycol-Free melphalan) as a preparative regimen for autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma" ($98,955).